Appl Environ Microbiol 1999, 65:351–354 PubMed 27 Lee YK, Ho PS,

Appl Environ Microbiol 1999, 65:351–354.PubMed 27. Lee YK, Ho PS, Low CS, Arvilommi H, Salminen S: Permanent colonization by Lactobacillus casei is hindered by the low rate of cell division in mouse gut. Appl Environ Microbiol 2004, 70:670–674.PubMedCrossRef 28. Ogawa T, Asai Y, Yasuda K: Oral immunoadjuvant activity of a new symbiotic Lactobacillus casei subsp casei in conjunction with dextran in BALB/c mice. Nutrition Research 2005, 25:295–304.CrossRef 29. Verweij WR, de Haan L, Holtrop M, Agsteribbe E, Brands R, van Scharrenburg GJ, Wilschut J: Mucosal SB431542 clinical trial immunoadjuvant activity of recombinant Escherichia coli heat-labile enterotoxin

and its B subunit: induction of systemic IgG and secretory IgA responses in mice by intranasal FHPI clinical trial immunization with influenza virus surface antigen. Vaccine 1998, 16:2069–2076.PubMedCrossRef 30. Tochikubo K, Isaka M, Yasuda Y, Kozuka S, Matano K, Miura Y, Taniguchi T: Recombinant cholera toxin B subunit acts as an adjuvant for the mucosal and systemic responses of mice to mucosally co-administered bovine serum albumin. Vaccine 1998, 16:150–155.PubMedCrossRef 31. Yamamoto M, McGhee JR, Hagiwara Y, Otake S, Kiyono H: Genetically manipulated bacterial toxin as a new generation mucosal adjuvant. Scand J Immunol 2001, 53:211–217.PubMedCrossRef 32.

de Haan L, Feil IK, Verweij WR, Holtrop M, Hol WG, Agsteribbe E, Wilschut J: Mutational analysis of the role of ADPribosylation activity and GM1-binding activity in the adjuvant properties of the Escherichia coli heat-labile enterotoxin towards intranasally administered keyhole limpet hemocyanin. Eur J Immunol 1998, 28:1243–1250.PubMedCrossRef 33. Saito K, Shoji J, Inada N, Iwasaki Y, Sawa M: Immunosuppressive effect of cholera toxin B on allergic conjunctivitis model in guinea pig. Jpn J Go6983 concentration Ophthalmol 2001, 45:332–338.PubMedCrossRef 34. Tamura S, Hatori E, Tsuruhara T, Aizawa C, Kurata T: Suppression of of delayed-type hypersensitivity and IgE antibody responses to ovalbumin by intranasal administration of Escherichia coli heat-labile enterotoxin B subunit-conjugated

ovalbumin. Vaccine 1997, 15:225–229.PubMedCrossRef 35. Douce G, Fontana M, Pizza M, Rappuoli R, Dougan G: Intranasal immunogenicity and adjuvanticity of site-directed mutant derivatives of cholera toxin. Infect Immun 1997, 65:2821–2828.PubMed 36. Mannam P, Jones KF, Geller BL: Mucosal vaccine made from live, recombinant Lactococcus lactis protects mice against pharyngeal infection with Streptococcus pyogenes. Infect Immun 2004, 72:3444–3450.PubMedCrossRef 37. Robinson K, Chamberlain LM, Schofield KM, Wells JM, Le Page RW: Oral vaccination of mice against tetanus with recombinant Lactococcus lactis. Nat Biotechnol 1997, 15:653–657.PubMedCrossRef 38. Seegers JF: Lactobacilli as live vaccine delivery vectors: progress and prospects.

Comments are closed.